Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00030550 · ClinicalTrials.gov registry record · Phase 2
Thalidomide in Treating Anemia in Patients With Myelodysplastic Syndrome
A Phase 2 study, sponsored by Roswell Park Cancer Institute.
- Completed
- Registry status
- Phase 2
- Development phase
NCT00030550: Completed Phase 2 study, sponsored by Roswell Park Cancer Institute.
NCT00030550 is a Phase 2 study that has completed, run by Roswell Park Cancer Institute. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00030550, a Phase 2 study, has completed, sponsored by Roswell Park Cancer Institute.
- COMPLETED
- Registry status
- Phase 2
- Development phase
Study Summary
RATIONALE: Thalidomide may be an effective treatment for anemia caused by myelodysplastic syndrome. PURPOSE: Randomized phase II trial to study the effectiveness of thalidomide in treating anemia in patients who have myelodysplastic syndrome.
Interventions
- DRUG thalidomide
Trial Details
| Field | Value |
|---|---|
| Start Date | 2001-09 |
| Phase | Phase 2 |
What the finished NCT00030550 record still lists
NCT00030550 is an interventional study that assigns participants to a tested intervention. An enrollment target was not published in the registry record, which is common for early-stage or observational entries.
The record links to 0 conditions, and to 1 intervention - of which thalidomide is the first listed.
NCT00030550 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00030550 about?
NCT00030550 is a clinical study titled "Thalidomide in Treating Anemia in Patients With Myelodysplastic Syndrome". RATIONALE: Thalidomide may be an effective treatment for anemia caused by myelodysplastic syndrome. PURPOSE: Randomized phase II trial to study the effectiveness of thalidomide in treating anemia in patients who have myelodysplastic syndrome.
What is the current status of trial NCT00030550?
This trial is currently completed. It is a Phase 2 study. The study started on 2001-09.
What interventions are being tested in trial NCT00030550?
The interventions under investigation include: thalidomide (DRUG).
Who is sponsoring clinical trial NCT00030550?
This trial is sponsored by Roswell Park Cancer Institute, which has 365 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia